Co-enzyme Supplements Effects on Blood Pressure: A Comparative Study

Abstract

Background: Blood pressure (BP) is a common and classic problem globally. Co-enzyme Q10 (Co-Q10) are organic molecules that have the ability to maintain the continuous oxidation-reduction cycle. The study aimed to assess the Co-Q10 effect in cases with pre-hypertension (pre-HTN).
Methods: A case-control study done in Al-Basrah teaching Hospital from 22nd Nov 2022 to 23rd of October 2023. In this study, 100 subjects were enrolled (60 males and 40 females) with age ranged between 28 and 71 years. Their BP ≥ 140 and ≤ 90 mmHg. The cases were detected clinically by a practitioner doctor as pre-HTN. Features for the diagnosis of pre-HTN upon the ACC/AHA guidelines in 2017 for different HTN phases. Three-month follow-up of 50 cases that underwent diet control and lifestyle modifications whereas 50 cases received Co-Q10 (ubiquinone, Liquidsun, Stamford, UK, Cat. No. 320274) 200 mg per day. Both systolic and diastolic BP were measured and recorded for all cases at base line of the study and post 3 months of administrator of Co-Q10. Results: The data showed a significant statistical difference in systolic and diastolic BP (p < 0.01), between both arms. A massive drop in the systolic and diastolic BP at the end of 3 months when compared with base-line records in the Co-Q10 group.
Conclusion: The daily administration of Co-Q10 enhance the reduction of both systolic and diastolic BP within pre-HTN cases.